Published in Vaccine on February 27, 2007
Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol (2009) 1.45
Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol (2007) 1.41
Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J Virol (2009) 1.19
The curious case of arenavirus entry, and its inhibition. Viruses (2012) 1.11
Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology (2011) 1.10
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine (2008) 1.09
A small nonhuman primate model for filovirus-induced disease. Virology (2011) 1.03
Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res (2011) 0.94
Human hemorrhagic Fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis. Pathogens (2015) 0.92
Development of live-attenuated arenavirus vaccines based on codon deoptimization. J Virol (2015) 0.91
An animal model that reflects human disease: the common marmoset (Callithrix jacchus). Curr Opin Virol (2012) 0.91
Advanced vaccine candidates for Lassa fever. Viruses (2012) 0.90
Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine (2010) 0.90
Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. Antiviral Res (2011) 0.88
An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J (2013) 0.86
Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate. PLoS Negl Trop Dis (2013) 0.85
Exploring kinase inhibitors as therapies for human arenavirus infections. Future Virol (2008) 0.85
Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines. J Virol (2015) 0.82
Comparative pathogenesis and systems biology for biodefense virus vaccine development. J Biomed Biotechnol (2010) 0.82
A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis (2015) 0.80
Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. J Vaccines Vaccin (2012) 0.79
Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein. Virology (2016) 0.75
Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man. Future Virol (2015) 0.75
Vaccines and me. Hum Vaccin Immunother (2016) 0.75
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38
Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature (2003) 4.60
The biology of lymphocytic choriomeningitis infection: virus-induced immune disease. Cold Spring Harb Symp Quant Biol (1962) 4.38
Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J Virol (1995) 3.90
The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci U S A (2001) 3.43
Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol (2001) 3.41
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Lassa fever. Curr Top Microbiol Immunol (2002) 3.01
Genetic diversity among Lassa virus strains. J Virol (2000) 3.00
Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J Virol (1989) 2.79
Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis (2000) 2.69
Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol (1994) 2.65
Genetic reassortment of Rift Valley fever virus in nature. J Virol (1999) 2.43
Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol (1997) 2.36
The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol (2001) 2.29
Lassa fever: epidemiology, clinical features, and social consequences. BMJ (2003) 2.06
Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol (2004) 1.96
Ngari virus is a Bunyamwera virus reassortant that can be associated with large outbreaks of hemorrhagic fever in Africa. J Virol (2004) 1.93
Virus-induced transient bone marrow aplasia: major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus. J Exp Med (1997) 1.93
Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol (1987) 1.83
Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine (1990) 1.82
Effective vaccine for lassa fever. J Virol (2000) 1.74
Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am J Trop Med Hyg (1996) 1.70
Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology (1986) 1.69
Historical Lassa fever reports and 30-year clinical update. Emerg Infect Dis (2006) 1.67
Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol (2001) 1.66
Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J Med Virol (1999) 1.65
Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J Virol (1985) 1.60
Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and to gamma interferon. J Virol (1994) 1.56
Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun (1982) 1.47
Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5' End. Virology (1997) 1.44
Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. J Med Virol (1993) 1.43
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol (2005) 1.42
Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology (2003) 1.40
High genetic divergence and recombination in Arenaviruses from the Americas. Virology (2002) 1.37
Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products. Virus Res (1991) 1.37
Generation of reassortants between African arenaviruses. Virology (1992) 1.33
Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol (2004) 1.30
The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum. J Gen Virol (1997) 1.29
Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet (1987) 1.28
Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection. J Virol (2004) 1.27
Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol (2000) 1.24
Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect (2006) 1.20
Molecular phylogeny of the arenaviruses. Curr Top Microbiol Immunol (2002) 1.17
Evidence of segment reassortment in Crimean-Congo haemorrhagic fever virus. J Gen Virol (2004) 1.17
Phylogeny and evolution of old world arenaviruses. Virology (2006) 1.15
Bystander sensitization to activation-induced cell death as a mechanism of virus-induced immune suppression. J Virol (2000) 1.13
Towards a human Lassa fever vaccine. Rev Med Virol (2001) 1.12
Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide. Eur J Immunol (1991) 1.10
Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology (2004) 1.09
Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol (2006) 1.07
New insights into the evolutionary relationships between arenaviruses provided by comparative analysis of small and large segment sequences. Virology (2003) 1.07
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology (2006) 1.06
Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus. J Virol (1993) 1.06
CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirus. J Immunol (2006) 1.06
Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology (2005) 1.03
Reassortant analysis of guinea pig virulence of pichinde virus variants. Virology (2001) 1.02
Prediction of arenavirus fusion peptides on the basis of computer analysis of envelope protein sequences. FEBS Lett (1990) 1.01
Very virulent infectious bursal disease virus: reduced pathogenicity in a rare natural segment-B-reassorted isolate. J Gen Virol (2006) 1.00
Characterization of arenaviruses using a family-specific primer set for RT-PCR amplification and RFLP analysis. Its potential use for detection of uncharacterized arenaviruses. Virus Res (1997) 0.94
Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol (1992) 0.94
LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration. Arch Virol (2004) 0.94
Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein. Vaccine (2000) 0.94
Ribonucleic acids of Machupo and Lassa viruses. Arch Virol (1984) 0.93
Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J Hum Virol (2001) 0.91
Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice. Clin Diagn Lab Immunol (2005) 0.91
[Activity of lymphocytic choriomeningitis virus (LCM) in the endemic area of Argentine hemorrhagic fever (AHF). I. Serological studies in rodents captured in the City of Pergamino]. Medicina (B Aires) (1972) 0.91
Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8 T cell-mediated, TNF-dependent immunopathology. J Clin Invest (2006) 0.89
Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes (2006) 0.88
Some biochemical properties of Lassa virus RNA and polypeptides. Med Microbiol Immunol (1986) 0.86
Update on Lassa fever in West Africa. Wkly Epidemiol Rec (2005) 0.84
Sedimentation analysis of the RNAs isolated from interfering particles of Lassa and Machupo viruses. Acta Virol (1985) 0.78
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol (2002) 2.77
Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci (2003) 2.67
Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci (2009) 2.08
Housing density does not influence the longevity effect of calorie restriction. J Gerontol A Biol Sci Med Sci (2005) 1.85
Spontaneous heart disease in the adult chimpanzee (Pan troglodytes). J Med Primatol (2008) 1.72
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol (2003) 1.56
Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin Vaccine Immunol (2006) 1.50
Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A (2009) 1.45
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol (2005) 1.42
Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol (2007) 1.41
Does reduced IGF-1R signaling in Igf1r+/- mice alter aging? PLoS One (2011) 1.39
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
Spontaneous neoplasia in the baboon (Papio spp.). J Med Primatol (2007) 1.34
Ebola virus matrix protein VP40 uses the COPII transport system for its intracellular transport. Cell Host Microbe (2008) 1.31
Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun (2005) 1.28
Effects of promyelocytic leukemia protein on virus-host balance. J Virol (2002) 1.28
Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol (2014) 1.27
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol (2003) 1.25
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Early blood profiles of virus infection in a monkey model for Lassa fever. J Virol (2007) 1.20
Forging a novel provider and payer partnership in Wisconsin to compensate pharmacists for quality-driven pharmacy and medication therapy management services. J Am Pharm Assoc (2003) (2009) 1.17
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Non-human primate fetal kidney transcriptome analysis indicates mammalian target of rapamycin (mTOR) is a central nutrient-responsive pathway. J Physiol (2006) 1.15
Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration. J Biol Chem (2007) 1.14
Requirement of glycosylphosphatidylinositol anchor of Cripto-1 for trans activity as a Nodal co-receptor. J Biol Chem (2007) 1.14
Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line. Prostate (2006) 1.14
A review of spontaneous neoplasia in baboons (Papio spp.). J Med Primatol (2005) 1.13
Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol (2013) 1.11
Effects of maternal global nutrient restriction on fetal baboon hepatic insulin-like growth factor system genes and gene products. Endocrinology (2009) 1.11
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
A role for the C terminus of Mopeia virus nucleoprotein in its incorporation into Z protein-induced virus-like particles. J Virol (2010) 1.10
Common marmosets (Callithrix jacchus) as a nonhuman primate model to assess the virulence of eastern equine encephalitis virus strains. J Virol (2008) 1.10
Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol (2010) 1.09
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine (2008) 1.09
Smad2 functions as a co-activator of canonical Wnt/beta-catenin signaling pathway independent of Smad4 through histone acetyltransferase activity of p300. Cell Signal (2008) 1.08
A novel Brucella isolate in association with two cases of stillbirth in non-human primates - first report. J Med Primatol (2009) 1.07
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology (2006) 1.06
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother (2005) 1.05
A small nonhuman primate model for filovirus-induced disease. Virology (2011) 1.03
Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1. J Cell Biol (2009) 1.03
Rapid assembly of sensitive antigen-capture assays for Marburg virus, using in vitro selection of llama single-domain antibodies, at biosafety level 4. J Infect Dis (2007) 1.02
Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology (2009) 1.02
Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J Med Virol (2002) 1.01
Past, present, and future of arenavirus taxonomy. Arch Virol (2015) 1.00
Short report: quantification of leishmaniavirus RNA in clinical samples and its possible role in pathogenesis. Am J Trop Med Hyg (2003) 1.00
Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells (2010) 0.99
Thioredoxin 1 overexpression extends mainly the earlier part of life span in mice. J Gerontol A Biol Sci Med Sci (2011) 0.99
The prolonged effect of repeated maternal glucocorticoid exposure on the maternal and fetal leptin/insulin-like growth factor axis in Papio species. Reprod Sci (2008) 0.99
Arenavirus variations due to host-specific adaptation. Viruses (2013) 0.99
Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells. J Cell Physiol (2008) 0.99
RNA binding domain of Jamestown Canyon virus S segment RNAs. J Virol (2007) 0.99
Spontaneous pathology of the common marmoset (Callithrix jacchus) and tamarins (Saguinus oedipus, Saguinus mystax). J Med Primatol (2009) 0.98
Mortality in captive baboons with seizures: a new model for SUDEP? Epilepsia (2009) 0.98
A novel adenovirus species associated with an acute respiratory outbreak in a baboon colony and evidence of coincident human infection. MBio (2013) 0.98
Natural Chagas disease in four baboons. J Med Primatol (2008) 0.97
Gene expression in primate liver during viral hemorrhagic fever. Virol J (2009) 0.97
Review article: Renal support in critical illness. Can J Anaesth (2010) 0.97
The frequency of lymphocytic and reflux esophagitis in non-human primates. Int J Clin Exp Pathol (2008) 0.97
Vaccinia virus inhibits T cell receptor-dependent responses by human gammadelta T cells. J Infect Dis (2006) 0.97
HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand. Intervirology (2007) 0.97
Natural pathology of the Baboon (Papio spp.). J Med Primatol (2011) 0.96
Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. Am J Pathol (2009) 0.96
Combination therapy reduces self-injurious behavior in a chimpanzee (Pan Troglodytes Troglodytes): a case report. J Appl Anim Welf Sci (2007) 0.96
Trypanosoma cruzi in non-human primates with a history of stillbirths: a retrospective study (Papio hamadryas spp.) and case report (Macaca fascicularis). J Med Primatol (2008) 0.95
The columnar-lined mucosa in the distal esophagus. A preliminary study in baboons. In Vivo (2009) 0.94
Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques. J Virol (2015) 0.94
The baboon model (Papio hamadryas) of fetal loss: maternal weight, age, reproductive history and pregnancy outcome. J Med Primatol (2008) 0.94
A case report of hepatocellular carcinoma and focal nodular hyperplasia with a myelolipoma in two chimpanzees and a review of spontaneous hepatobiliary tumors in non-human primates. J Med Primatol (2004) 0.93
Reductions in serum IGF-1 during aging impair health span. Aging Cell (2013) 0.93
Endothelial senescence after high-cholesterol, high-fat diet challenge in baboons. Am J Physiol Heart Circ Physiol (2007) 0.93
Increased virus replication and virulence after serial passage of human immunodeficiency virus type 2 in baboons. J Virol (2003) 0.93
Do long-lived mutant and calorie-restricted mice share common anti-aging mechanisms?--a pathological point of view. Age (Dordr) (2006) 0.92